Study guide
7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation
Key Takeaways Explain This Topic AI
Maternal physiological adaptations expand plasma volume, increase renal GFR by 50-80%, alter CYP450 activity, and accelerate clearance, frequently requiring dosage increases for renally eliminated drugs and lamotrigine.
Teratogenic risk is greatest during the embryonic period of organogenesis (gestational weeks 5 to 10), whereas exposure during the first 2 weeks post-conception follows an 'all-or-none' rule.
Major proven human teratogens include ACE inhibitors/ARBs (fetal renal dysgenesis/oligohydramnios), valproic acid (neural tube defects, autism), isotretinoin (craniofacial/cardiac anomalies), warfarin (fetal warfarin syndrome), and third-trimester NSAIDs (premature ductus arteriosus closure).
First-line safer options in pregnancy include labetalol/nifedipine for hypertension, insulin for diabetes, LMWH for anticoagulation, and doxylamine/pyridoxine (Diclectin) for nausea/vomiting.
In breastfeeding, a Relative Infant Dose (RID) under 10% is generally acceptable; codeine and tramadol are strictly contraindicated due to maternal CYP2D6 ultra-rapid metabolizer-induced fatal infant morphine overdoses.
Last updated: August 2026
Maternal Pharmacokinetics and Physiological Adaptations
Pregnancy triggers profound anatomical and endocrine changes designed to support fetal growth. These physiological adaptations alter drug absorption, distribution, metabolism, and elimination across all three trimesters. +-------------------------------------------------------------------------+
- | MATERNAL PHARMACOKINETIC (PK) ADAPTATIONS |
- +-------------------------------------------------------------------------+
- | ABSORPTION: |
- | - Elevated progesterone slows gastric emptying and GI transit time |
- | - Increased gastric pH (decreased gastric acid secretion) |
- | - Increased pulmonary blood flow -> enhanced inhaled drug absorption |
- | |
- | DISTRIBUTION: |
- | - Plasma volume expands by 40-50% (plasma +1.5 L) |
- | - Total body water expands by 6-8 L; maternal adipose +3-4 kg |
- | - Expanded Vd for both hydrophilic and lipophilic drugs |
- | - Serum albumin falls (hypoalbuminemia of pregnancy) -> higher free |
- | active fraction of protein-bound drugs (phenytoin, valproate) |
- | |
- | METABOLISM: |
- | - INDUCED ENZYMES (Increased Clearance): CYP3A4, CYP2D6, CYP2C9, UGT |
- | -> Lamotrigine glucuronidation (UGT1A4) surges up to 300% -> |
- | drastic drop in serum level; seizures occur if dose not increased |
- | - INHIBITED ENZYMES (Decreased Clearance): CYP1A2, CYP2C19 |
- | -> Prolonged half-life of caffeine, theophylline |
- | |
- | EXCRETION: |
- | - Renal blood flow and GFR increase by 50-80% starting in 1st trimester|
- | - Dramatically accelerated clearance of renally eliminated drugs |
- | (lithium, penicillins, cephalosporins, enoxaparin, digoxin) |
- | - Frequently requires HIGHER doses and SHORTER dosing intervals |
- +-------------------------------------------------------------------------+
- Clinical Impact on Medication Dosing
Lamotrigine Dosing Surge: Estrogen powerfully induces UGT1A4 , the primary enzyme responsible for lamotrigine glucuronidation. Serum lamotrigine concentrations fall by 50 − 70 % 50-70\% 50 − 70% as early as the first trimester, precipitating loss of seizure control. Frequent therapeutic drug monitoring and dosage increases of up to 200 − 300 % 200-300\% 200 − 300% of pre-pregnancy baselines are required, followed by immediate postpartum dose tapering to avoid postpartum toxicity as estrogen levels plunge.
Accelerated Renal Clearance: Renally excreted drugs (e.g., ampicillin, cefazolin, low molecular weight heparins, lithium ) have significantly shortened elimination half-lives and lower trough concentrations, necessitating increased daily doses or more frequent administration (e.g., every 8 hours instead of every 12 hours).
- Placental Drug Transfer and Teratogenic Mechanisms
- Determinants of Placental Transfer
The human placenta is a lipid membrane separating maternal and fetal circulations. The vast majority of medications cross the placenta by passive diffusion :
Molecular Weight ( M W MW M W ): Drugs with M W < 500 Da MW < 500\text{ Da} M W < 500 Da cross the placenta readily (most conventional small-molecule drugs). Drugs with M W 500 − 1000 Da MW 500-1000\text{ Da} M W 500 − 1000 Da cross more slowly. Large macromolecules with M W > 1000 Da MW > 1000\text{ Da} M W > 1000 Da (such as insulin, heparin, certolizumab pegol ) do not cross the placenta in clinically significant amounts.
Lipid Solubility: Highly lipophilic medications (e.g., general anesthetics, opioids, benzodiazepines) rapidly traverse the syncytiotrophoblast.
Ionization: Non-ionized drugs cross more rapidly. Fetal blood is slightly more acidic ( pH 7.30 − 7.35 \text{pH } 7.30-7.35 pH 7.30 − 7.35 ) than maternal blood ( pH 7.40 \text{pH } 7.40 pH 7.40 ), causing weak bases to become ionized in fetal circulation, leading to ion trapping and higher fetal drug accumulation.
Protein Binding: Only the unbound (free) fraction crosses the placenta.
Critical Timing of Teratogenic Exposure +-------------------------------------------------------------------------+
- | CRITICAL PERIODS OF GESTATIONAL EXPOSURE |
- +-------------------------------------------------------------------------+
- | |
- | 1. PRE-DIFFERENTIATION / PRE-IMPLANTATION (Fertilization to Day 14): |
- | - 'ALL-OR-NONE' Period |
- | - Severe toxic insults destroy the blastocyst (spontaneous abortion)|
- | - Non-lethal insults are repaired by totipotent cells (normal baby) |
- | - Major structural anatomical malformations do NOT occur |
- | |
- | 2. EMBRYONIC PERIOD / ORGANOGENESIS (Weeks 3 to 8 post-conception; |
- | Gestational Weeks 5 to 10): |
- | - CRITICAL WINDOW FOR MAJOR STRUCTURAL TERATOGENESIS |
- | - Organs undergo primary morphogenesis: |
- | * Neural Tube: Days 18-28 (Folic acid critical!) |
- | * Heart: Days 20-40 |
- | * Limbs: Days 24-36 |
- | * Palate & Facial Structures: Days 40-60 |
- | - Exposure to teratogens produces gross anatomical defects |
- | |
- | 3. FETAL PERIOD (Week 9 to Delivery): |
- | - Organs are formed; undergo growth, differentiation, & maturation |
- | - Teratogenic insults cause functional deficits, growth restriction,|
- | CNS behavioral alterations, and fetotoxicity (e.g., ACEi fetopathy|
- | or NSAID-induced ductus arteriosus constriction) |
- +-------------------------------------------------------------------------+
- High-Yield Teratogens and Evidence-Based Canadian Management
- Major Known Teratogens Matrix
Teratogenic Agent Critical Exposure Window Classic Malformation / Fetotoxicity Pattern
ACE Inhibitors & ARBs (e.g., Ramipril, Valsartan) 2nd & 3rd Trimesters Renin-Angiotensin Fetopathy: Fetal renal tubular dysgenesis, severe oligohydramnios, pulmonary hypoplasia, neonatal anuria/renal failure, calvarial (skull) bone hypoplasia, limb contractures
Valproic Acid 1st Trimester Highest teratogenic risk among AEDs ( 10 − 15 % 10-15\% 10 − 15% malformations): Neural tube defects (spina bifida, 1 − 2 % 1-2\% 1 − 2% ), craniofacial dysmorphism, cardiac defects, cleft palate, and severe neurodevelopmental deficits / reduced IQ / autism spectrum disorders
Isotretinoin & Retinoids 1st Trimester Retinoic Acid Embryopathy ( > 30 % > 30\% > 30% risk): Microtia/anotia (absent/small ears), micrognathia, thymic aplasia, conotruncal cardiovascular defects (transposition of great vessels), hydrocephalus
Warfarin 1st Trimester (Weeks 6-9) & 2nd/3rd Trimesters Fetal Warfarin Syndrome: Nasal hypoplasia, stippled epiphyses (chondrodysplasia punctata), optic atrophy, microcephaly, intracranial hemorrhage
Thalidomide Days 20-36 post-conception Phocomelia (seal-like limb reduction, absent long bones), amelia, anotia, cardiac and gastrointestinal malformations
Methotrexate 1st Trimester Fetal Methotrexate Syndrome: Craniosynostosis, wide fontanelles, micrognathia, limb hypoplasia, severe intrauterine growth restriction
NSAIDs (e.g., Naproxen, Ibuprofen, Celecoxib) Late 2nd & 3rd Trimesters ( > 20 − 28 weeks > 20-28\text{ weeks} > 20 − 28 weeks ) Premature closure of the ductus arteriosus , persistent pulmonary hypertension of the newborn (PPHN), and fetal renal impairment causing oligohydramnios
Lithium 1st Trimester Ebstein's Anomaly (downward displacement of tricuspid valve leaflets into right ventricle; absolute risk ∼ 1 in 1000 \sim 1\text{ in }1000 ∼ 1 in 1000 , lower than historically quoted but significant)
Clinical Management of Chronic Conditions in Pregnancy (SOGC Guidelines)
Hypertension in Pregnancy (Chronic or Gestational):
First-Line Oral Agents: Labetalol (combined α / β \alpha/\beta α / β -blocker; 100 − 400 mg 100-400\text{ mg} 100 − 400 mg PO BID-TID), Methyldopa (central α 2 \alpha_2 α 2 -agonist; 250 − 500 mg 250-500\text{ mg} 250 − 500 mg PO BID-QID), and Long-Acting Nifedipine (dihydropyridine CCB; 20 − 60 mg 20-60\text{ mg} 20 − 60 mg daily XL).
Severe Acute Hypertension ( BP ≥ 160 / 110 mmHg \text{BP} \ge 160/110\text{ mmHg} BP ≥ 160/110 mmHg ): Labetalol IV , Hydralazine IV , or Nifedipine intermediate-release PO .
Strictly Contraindicated: ACE inhibitors, ARBs, and Direct Renin Inhibitors.
Diabetes in Pregnancy (Gestational and Pregestational):
Insulin is the gold standard (does not cross the placenta; NPH, Regular, Detemir, Glargine, Lispro, Aspart). Metformin and glyburide cross the placenta and are second-line alternatives when insulin is refused or unmanageable.
Venous Thromboembolism (VTE) & Anticoagulation:
Low Molecular Weight Heparin (LMWH, e.g., Enoxaparin, Dalteparin) is the standard of care (does not cross placenta, predictable PK, lower heparin-induced thrombocytopenia and bone loss risks). Unfractionated heparin is used near term. DOACs and warfarin are avoided.
Nausea and Vomiting of Pregnancy (NVP):
First-Line: Doxylamine succinate 10 mg 10\text{ mg} 10 mg / Pyridoxine hydrochloride 10 mg 10\text{ mg} 10 mg ( Diclectin , up to 4 tablets daily per SOGC guidelines).
Second-Line: Dimenhydrinate ( 50 − 100 mg 50-100\text{ mg} 50 − 100 mg PO/PR q4-6h), Promethazine, Metoclopramide, or Ondansetron.
Folic Acid Supplementation for Neural Tube Defect (NTD) Prevention:
Low-Risk Women: 0.4 mg 0.4\text{ mg} 0.4 mg ( 400 μ g 400\text{ }\mu\text{g} 400 μ g ) PO daily starting at least 2 to 3 months prior to conception throughout pregnancy and postpartum.
Moderate Risk (Diabetes, obesity, GI malabsorption, family history): 1.0 mg 1.0\text{ mg} 1.0 mg PO daily.
High Risk (Personal history of prior NTD pregnancy, or taking valproate/carbamazepine): 4.0 − 5.0 mg 4.0-5.0\text{ mg} 4.0 − 5.0 mg PO daily pre-conception until 12 weeks gestation, then 0.4 − 1.0 mg 0.4-1.0\text{ mg} 0.4 − 1.0 mg daily throughout pregnancy.